Sesen Bio Inc (NASDAQ:SESN)’s share price was down 6.8% on Wednesday . The company traded as low as $1.85 and last traded at $1.91. Approximately 4,406,808 shares traded hands during mid-day trading, an increase of 76% from the average daily volume of 2,505,867 shares. The stock had previously closed at $2.05.

A number of equities analysts have recently weighed in on SESN shares. Zacks Investment Research raised Sesen Bio from a “hold” rating to a “buy” rating and set a $1.50 price objective for the company in a research note on Friday, May 17th. HC Wainwright raised Sesen Bio from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $1.00 to $3.00 in a research note on Tuesday. Finally, ValuEngine lowered Sesen Bio from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $2.50.

The company has a market capitalization of $146.94 million, a price-to-earnings ratio of -3.47 and a beta of 1.14.

Sesen Bio (NASDAQ:SESN) last released its quarterly earnings data on Monday, May 13th. The company reported ($0.08) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.08). Sell-side analysts anticipate that Sesen Bio Inc will post -0.31 EPS for the current year.

A number of institutional investors have recently made changes to their positions in SESN. Vanguard Group Inc boosted its stake in Sesen Bio by 22.0% during the third quarter. Vanguard Group Inc now owns 2,518,891 shares of the company’s stock valued at $5,415,000 after buying an additional 454,950 shares during the last quarter. Vanguard Group Inc. boosted its stake in Sesen Bio by 22.0% during the third quarter. Vanguard Group Inc. now owns 2,518,891 shares of the company’s stock valued at $5,415,000 after buying an additional 454,950 shares during the last quarter. Millennium Management LLC boosted its stake in Sesen Bio by 32.5% during the fourth quarter. Millennium Management LLC now owns 1,099,897 shares of the company’s stock valued at $1,562,000 after buying an additional 269,863 shares during the last quarter. Castle Hook Partners LP boosted its stake in Sesen Bio by 24.7% during the first quarter. Castle Hook Partners LP now owns 1,262,924 shares of the company’s stock valued at $1,301,000 after buying an additional 250,000 shares during the last quarter. Finally, Pura Vida Investments LLC bought a new position in Sesen Bio during the fourth quarter valued at approximately $284,000. 24.14% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Sesen Bio (NASDAQ:SESN) Shares Down 6.8%” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2019/06/12/sesen-bio-nasdaqsesn-shares-down-6-8.html.

Sesen Bio Company Profile (NASDAQ:SESN)

Sesen Bio, Inc, a late-stage clinical company, develops next-generation antibody-drug conjugate therapies for patients with cancer. It develops its products based on its Targeted Protein Therapeutics (TPTs) platform. The company's lead product candidate is Vicinium, a fusion protein that is in Phase III clinical trial for the treatment of high-grade non-muscle invasive bladder cancer.

See Also: What is a capital gains distribution?

Receive News & Ratings for Sesen Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sesen Bio and related companies with MarketBeat.com's FREE daily email newsletter.